Save up to 80% by drug discount in your pharmacy with "Pharmacy Near Me - National Drug Discount Card"
You can scan QR Code(just open camera on your phone/scan by application) from the image on prescription drug discount card to save it to your mobile phone. Or just click on image if you're on mobile phone.
| Product NDC Code | 0023-5861 | ||||
|---|---|---|---|---|---|
| Drug Name | Gelnique |
||||
| Type | Brand | ||||
| Pharm Class | Cholinergic Muscarinic Antagonist [EPC], Cholinergic Muscarinic Antagonists [MoA] |
||||
| Active Ingredients |
|
||||
| Route | TRANSDERMAL | ||||
| Dosage Form | GEL | ||||
| RxCUI drug identifier | 864818, 864820 |
||||
| Application Number | NDA022204 | ||||
| Labeler Name | Allergan, Inc. | ||||
| Packages |
|
||||
| Check if available Online | Get Medication Prices online with Discount |
Overdosage of GELNIQUE
Information about signs, symptoms, and laboratory findings of acute ovedosage and the general principles of overdose treatment.10 OVERDOSAGE Overdosage with oxybutynin has been associated with anticholinergic effects including central nervous system excitation, flushing, fever, dehydration, cardiac arrhythmia, vomiting, and urinary retention. Oral ingestion of 100 mg oxybutynin chloride in association with alcohol has been reported in a 13-year-old boy who experienced memory loss, and in a 34-year-old woman who developed stupor, followed by disorientation and agitation on awakening, dilated pupils, dry skin, cardiac arrhythmia, and retention of urine. Both patients recovered fully with symptomatic treatment. Plasma concentrations of oxybutynin begin to decline 24 hours after GELNIQUE application. If overexposure occurs, monitor patients until symptoms resolve.
Adverse reactions
Information about undesirable effects, reasonably associated with use of the drug, that may occur as part of the pharmacological action of the drug or may be unpredictable in its occurrence. Adverse reactions include those that occur with the drug, and if applicable, with drugs in the same pharmacologically active and chemically related class. There is considerable variation in the listing of adverse reactions. They may be categorized by organ system, by severity of reaction, by frequency, by toxicological mechanism, or by a combination of these.6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice. The most common adverse reactions (incidence > 5% and > placebo) were dry mouth, urinary tract infection, and application site reactions. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience The safety of GELNIQUE was evaluated in 789 patients (389 randomized to GELNIQUE 1 g and 400 randomized to placebo) during a randomized, placebo-controlled, double-blind, 12-week clinical efficacy and safety study. A subset of these 789 patients (N = 216) participated in the 14-week open-label safety extension that followed the placebo-controlled study. Of 216 patients in the safety extension, 107 were randomized to placebo gel during the double-blind, placebo-controlled 12-week study. In the combined double-blind, placebo-controlled study and the open-label safety extension, a total of 496 patients were exposed to at least one dose of GELNIQUE. Four hundred thirty-one (431) patients received at least 12 weeks of GELNIQUE treatment and 85 patients received 26 weeks of GELNIQUE treatment. The study population primarily consisted of Caucasian women (approximately 90%) with an average age of 59 years who had overactive bladder with urge urinary incontinence. Table 1 lists adverse reactions that were reported in the randomized, double-blind, placebo-controlled 12-week study in greater than 2% of patients treated with GELNIQUE and at an incidence greater than placebo. Table 1: Common Adverse Reactions in the Randomized, Double-blind, Placebo-controlled 12-Week Study (> 2% and > placebo) Adverse Reaction GELNIQUE 1 gram N = 389 n (%) Placebo N = 400 n (%) Dry mouth 29 (7.5) 11 (2.8) Urinary tract infection 27 (6.9) 17 (4.3) Application site reactions* 21 (5.4) 4 (1.0) Upper respiratory tract infection 21 (5.4) 20 (5.0) Dizziness 11 (2.8) 4 (1.0) Nasopharyngitis 11 (2.8) 9 (2.3) Fatigue 8 (2.1) 4 (1.0) Gastroenteritis viral 8 (2.1) 7 (1.8) * Includes application site pruritus, dermatitis, papules, anesthesia, erythema, irritation, pain and papules Other common adverse reactions that were reported in ≥ 1% of GELNIQUE-treated patients were headache (1.5%), constipation (1.3%), and pruritus (1.3%). Application site pruritus (2.1%) and application site dermatitis (1.8%) were the most commonly reported application site reactions. A majority of adverse reactions were described as mild or moderate in intensity, except for two patients reporting severe headache. The most common adverse reaction leading to drug discontinuation was application site reaction (0.8% with GELNIQUE versus 0.3% with placebo). The most common adverse reactions reported during the 14-week open-label extension study were application site reactions (6.0%) and dry mouth (1.9%). The most common reason for premature discontinuation was application site reactions (9 patients or 4.2%). Two of these 9 patients experienced application site reactions of severe intensity (dermatitis, urticaria, and erythema). 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of GELNIQUE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Nervous System Disorders: Memory impairment, dizziness, somnolence, confusion Psychiatric Disorders: Delirium, hallucinations
| | | |
| Dry mouth | 29 (7.5) | 11 (2.8) |
| Urinary tract infection | 27 (6.9) | 17 (4.3) |
| Application site reactions* | 21 (5.4) | 4 (1.0) |
| Upper respiratory tract infection | 21 (5.4) | 20 (5.0) |
| Dizziness | 11 (2.8) | 4 (1.0) |
| Nasopharyngitis | 11 (2.8) | 9 (2.3) |
| Fatigue | 8 (2.1) | 4 (1.0) |
| Gastroenteritis viral | 8 (2.1) | 7 (1.8) |
| * Includes application site pruritus, dermatitis, papules, anesthesia, erythema, irritation, pain and papules | ||
GELNIQUE Drug Interactions
Information about and practical guidance on preventing clinically significant drug/drug and drug/food interactions that may occur in people taking the drug.7 DRUG INTERACTIONS No specific drug-drug interaction studies have been performed with GELNIQUE. Other Anticholinergics (muscarinic antagonists): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects. ( 7.1 ) 7.1 Other Anticholinergics The concomitant use of GELNIQUE with other anticholinergic (antimuscarinic) agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, somnolence and other anticholinergic pharmacological effects. 7.2 Cytochrome P450 Inhibitors Pharmacokinetic studies have not been performed with patients concomitantly receiving cytochrome P450 enzyme inhibitors, such as antimycotic agents (e.g., ketoconazole, itraconazole, and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin).
Clinical pharmacology
Information about the clinical pharmacology and actions of the drug in humans.12 CLINICAL PHARMACOLOGY Figure 1 12.1 Mechanism of Action Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. Oxybutynin is a racemic (50:50) mixture of R- and S- isomers. Antimuscarinic activity resides predominantly with the R- isomer. The active metabolite, N-desethyloxybutynin, has pharmacological activity on the human detrusor muscle that is similar to that of oxybutynin in in vitro studies. 12.3 Pharmacokinetics Absorption Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum. Steady-state concentrations are achieved within 7 days of continuous dosing. Absorption of oxybutynin is similar when GELNIQUE is applied to the abdomen, upper arm/shoulders or thighs. Mean plasma concentrations during a randomized, crossover study of the three recommended application sites in 39 healthy men and women are shown in Figure 1. Average steady-state plasma oxybutynin concentrations were 4.7, 5.2, and 5.5 ng/mL for the abdomen, upper arm/shoulder and thigh application sites, respectively (Table 2). Table 2: Mean (SD) steady-state pharmacokinetic parameters for oxybutynin following GELNIQUE application to the abdomen, upper arm/shoulder and thigh (N = 39). Application Site AUC 0-24 (ng•hr/mL) C max (ng/mL) C avg (ng/mL) Abdomen 112.7 (58.00) 6.8 (3.93) 4.7 (2.39) Upper Arm/Shoulder 133.8 (81.58) 8.3 (5.97) 5.5 (3.37) Thigh 125.1 (84.67) 7.0 (4.95) 5.2 (3.50) Distribution Oxybutynin is widely distributed in body tissues following systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg oxybutynin chloride. Metabolism Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and N-desethyloxybutynin (DEO), which is pharmacologically active. Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyloxybutynin metabolite. Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transdermal absorption. The AUC ratio of N-desethyloxybutynin metabolite to parent compound following multiple transdermal applications is approximately 1:1 for GELNIQUE. Following intravenous administration, the elimination half-life of oxybutynin is approximately 2 hours. After the final steady-state dose of GELNIQUE, oxybutynin and N-desethyloxybutynin demonstrated biphasic elimination with plasma concentrations beginning to decrease 24 hours after dosing. Elimination was more rapid between 24 and 48 hours after dosing, during which time plasma concentrations of oxybutynin and N-desethyloxybutynin declined by about one-half. This rapid elimination phase was followed by a more prolonged terminal elimination phase. The apparent elimination half-lives including the terminal elimination phase were 64 hours and 82 hours for oxybutynin and DEO, respectively. Excretion Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin. Person-to-Person Transference The potential for dermal transfer of oxybutynin from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with GELNIQUE engaged in vigorous contact with an untreated partner for 15 minutes, either with (N = 14 couples) or without (N = 12 couples) clothing covering the application area. The untreated partners not protected by clothing demonstrated detectable plasma concentrations of oxybutynin (mean C max = 0.94 ng/mL). Two of the 14 untreated subjects participating in the clothing-to-skin contact regimen had measurable oxybutynin plasma concentrations (C max ≤ 0.1 ng/mL) during the 48 hours following contact with treated subjects; oxybutynin was not detectable with the remaining 12 untreated subjects. Use of Sunscreen The effect of sunscreen on the absorption of oxybutynin when applied 30 minutes before or 30 minutes after GELNIQUE application was evaluated in a single-dose randomized crossover study (N = 16). Concomitant application of sunscreen, either before or after GELNIQUE application, had no effect on the systemic exposure of oxybutynin. Showering The effect of showering on the absorption of oxybutynin was evaluated in a randomized, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after GELNIQUE application (N = 20). The results of the study indicate that showering after one hour does not affect the overall systemic exposure to oxybutynin. Race The effect of race on the pharmacokinetics of GELNIQUE has not been studied. Specific Populations: Geriatric: Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on geriatric status in patients following administration of GELNIQUE [see Use in Specific Populations (8.5) ]. Pediatric: The pharmacokinetics of oxybutynin and N-desethyloxybutynin have not been evaluated in individuals younger than 18 years of age [see Use in Specific Populations (8.4) ] . Gender: Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on gender in healthy volunteers following administration of GELNIQUE.
| | | | |
| Abdomen | 112.7 (58.00) | 6.8 (3.93) | 4.7 (2.39) |
| Upper Arm/Shoulder | 133.8 (81.58) | 8.3 (5.97) | 5.5 (3.37) |
| Thigh | 125.1 (84.67) | 7.0 (4.95) | 5.2 (3.50) |
Mechanism of action
Information about the established mechanism(s) of the drugÕs action in humans at various levels (for example receptor, membrane, tissue, organ, whole body). If the mechanism of action is not known, this field contains a statement about the lack of information.12.1 Mechanism of Action Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. Oxybutynin is a racemic (50:50) mixture of R- and S- isomers. Antimuscarinic activity resides predominantly with the R- isomer. The active metabolite, N-desethyloxybutynin, has pharmacological activity on the human detrusor muscle that is similar to that of oxybutynin in in vitro studies.
Pharmacokinetics
Information about the clinically significant pharmacokinetics of a drug or active metabolites, for instance pertinent absorption, distribution, metabolism, and excretion parameters.12.3 Pharmacokinetics Absorption Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum. Steady-state concentrations are achieved within 7 days of continuous dosing. Absorption of oxybutynin is similar when GELNIQUE is applied to the abdomen, upper arm/shoulders or thighs. Mean plasma concentrations during a randomized, crossover study of the three recommended application sites in 39 healthy men and women are shown in Figure 1. Average steady-state plasma oxybutynin concentrations were 4.7, 5.2, and 5.5 ng/mL for the abdomen, upper arm/shoulder and thigh application sites, respectively (Table 2). Table 2: Mean (SD) steady-state pharmacokinetic parameters for oxybutynin following GELNIQUE application to the abdomen, upper arm/shoulder and thigh (N = 39). Application Site AUC 0-24 (ng•hr/mL) C max (ng/mL) C avg (ng/mL) Abdomen 112.7 (58.00) 6.8 (3.93) 4.7 (2.39) Upper Arm/Shoulder 133.8 (81.58) 8.3 (5.97) 5.5 (3.37) Thigh 125.1 (84.67) 7.0 (4.95) 5.2 (3.50) Distribution Oxybutynin is widely distributed in body tissues following systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg oxybutynin chloride. Metabolism Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and N-desethyloxybutynin (DEO), which is pharmacologically active. Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyloxybutynin metabolite. Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transdermal absorption. The AUC ratio of N-desethyloxybutynin metabolite to parent compound following multiple transdermal applications is approximately 1:1 for GELNIQUE. Following intravenous administration, the elimination half-life of oxybutynin is approximately 2 hours. After the final steady-state dose of GELNIQUE, oxybutynin and N-desethyloxybutynin demonstrated biphasic elimination with plasma concentrations beginning to decrease 24 hours after dosing. Elimination was more rapid between 24 and 48 hours after dosing, during which time plasma concentrations of oxybutynin and N-desethyloxybutynin declined by about one-half. This rapid elimination phase was followed by a more prolonged terminal elimination phase. The apparent elimination half-lives including the terminal elimination phase were 64 hours and 82 hours for oxybutynin and DEO, respectively. Excretion Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin. Person-to-Person Transference The potential for dermal transfer of oxybutynin from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with GELNIQUE engaged in vigorous contact with an untreated partner for 15 minutes, either with (N = 14 couples) or without (N = 12 couples) clothing covering the application area. The untreated partners not protected by clothing demonstrated detectable plasma concentrations of oxybutynin (mean C max = 0.94 ng/mL). Two of the 14 untreated subjects participating in the clothing-to-skin contact regimen had measurable oxybutynin plasma concentrations (C max ≤ 0.1 ng/mL) during the 48 hours following contact with treated subjects; oxybutynin was not detectable with the remaining 12 untreated subjects. Use of Sunscreen The effect of sunscreen on the absorption of oxybutynin when applied 30 minutes before or 30 minutes after GELNIQUE application was evaluated in a single-dose randomized crossover study (N = 16). Concomitant application of sunscreen, either before or after GELNIQUE application, had no effect on the systemic exposure of oxybutynin. Showering The effect of showering on the absorption of oxybutynin was evaluated in a randomized, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after GELNIQUE application (N = 20). The results of the study indicate that showering after one hour does not affect the overall systemic exposure to oxybutynin. Race The effect of race on the pharmacokinetics of GELNIQUE has not been studied. Specific Populations: Geriatric: Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on geriatric status in patients following administration of GELNIQUE [see Use in Specific Populations (8.5) ]. Pediatric: The pharmacokinetics of oxybutynin and N-desethyloxybutynin have not been evaluated in individuals younger than 18 years of age [see Use in Specific Populations (8.4) ] . Gender: Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on gender in healthy volunteers following administration of GELNIQUE.
| | | | |
| Abdomen | 112.7 (58.00) | 6.8 (3.93) | 4.7 (2.39) |
| Upper Arm/Shoulder | 133.8 (81.58) | 8.3 (5.97) | 5.5 (3.37) |
| Thigh | 125.1 (84.67) | 7.0 (4.95) | 5.2 (3.50) |
Contraindications
Information about situations in which the drug product is contraindicated or should not be used because the risk of use clearly outweighs any possible benefit, including the type and nature of reactions that have been reported.4 CONTRAINDICATIONS The use of GELNIQUE is contraindicated in the following conditions: Urinary retention Gastric retention Uncontrolled narrow-angle glaucoma Known serious hypersensitivity reaction to GELNIQUE, oxybutynin, or to any of the components of GELNIQUE [ see Warnings and Precautions (5.3 , 5.4) ] . Urinary retention ( 4 ) Gastric retention ( 4 ) Uncontrolled narrow-angle glaucoma ( 4 ) Known serious hypersensitivity reaction to GELNIQUE, oxybutynin, or to any of the components of GELNIQUE ( 4 )
Description
General information about the drug product, including the proprietary and established name of the drug, the type of dosage form and route of administration to which the label applies, qualitative and quantitative ingredient information, the pharmacologic or therapeutic class of the drug, and the chemical name and structural formula of the drug.11 DESCRIPTION Oxybutynin is an antispasmodic, antimuscarinic agent. GELNIQUE (oxybutynin chloride) is a clear and colorless hydroalcoholic gel containing 100 mg oxybutynin chloride per gram of gel. GELNIQUE is available in a metered-dose pump that dispenses 30 metered 1 gram doses or in a 1 gram (1.14 mL) unit dose. Each dose contains 100 mg oxybutynin chloride. Oxybutynin is delivered as a racemate of R- and S- isomers. Chemically, oxybutynin chloride is d, l (racemic) 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate hydrochloride. The empirical formula of oxybutynin is C 22 H 31 NO 3 • HCl. Its structural formula is: Oxybutynin chloride is a white powder with a molecular weight of 393.95. Inactive ingredients in GELNIQUE are alcohol, USP; glycerin, USP; hydroxypropyl cellulose, NF; sodium hydroxide, NF; and purified water, USP. structural formula
Dosage and administration
Information about the drug product’s dosage and administration recommendations, including starting dose, dose range, titration regimens, and any other clinically sigificant information that affects dosing recommendations.2 DOSAGE AND ADMINISTRATION The contents of one sachet or one actuation of the metered-dose pump of GELNIQUE should be applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs. Application sites should be rotated. Application of GELNIQUE should not be made to the same site on consecutive days [ see Clinical Pharmacology (12.3) ] . GELNIQUE is for topical application only and should not be ingested. Apply contents of one sachet or one actuation of the metered-dose pump of GELNIQUE once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs. ( 2 ) Rotate application sites, avoiding use of the same site on consecutive days. ( 2 ) GELNIQUE is for topical application only and should not be ingested. ( 2 )
Dosage forms and strengths
Information about all available dosage forms and strengths for the drug product to which the labeling applies. This field may contain descriptions of product appearance.3 DOSAGE FORMS AND STRENGTHS Gel: 10% Gel: 10% ( 3 )
Indications and usage
A statement of each of the drug products indications for use, such as for the treatment, prevention, mitigation, cure, or diagnosis of a disease or condition, or of a manifestation of a recognized disease or condition, or for the relief of symptoms associated with a recognized disease or condition. This field may also describe any relevant limitations of use.1 INDICATIONS AND USAGE GELNIQUE is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency [ see Clinical Studies (14) ] . GELNIQUE is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )
Spl product data elements
Usually a list of ingredients in a drug product.GELNIQUE oxybutynin chloride OXYBUTYNIN CHLORIDE OXYBUTYNIN ALCOHOL GLYCERIN HYDROXYPROPYL CELLULOSE, UNSPECIFIED SODIUM HYDROXIDE WATER GELNIQUE oxybutynin chloride OXYBUTYNIN CHLORIDE OXYBUTYNIN ALCOHOL GLYCERIN HYDROXYPROPYL CELLULOSE, UNSPECIFIED SODIUM HYDROXIDE WATER
Carcinogenesis and mutagenesis and impairment of fertility
Information about carcinogenic, mutagenic, or fertility impairment potential revealed by studies in animals. Information from human data about such potential is part of the warnings field.13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A 24-month study in rats at dosages of oxybutynin chloride of 20, 80 and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25 and 50 times the maximum exposure in humans taking an oral dose, based on body surface area. Oxybutynin chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems. Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no definite evidence of impaired fertility.
Nonclinical toxicology
Information about toxicology in non-human subjects.13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A 24-month study in rats at dosages of oxybutynin chloride of 20, 80 and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25 and 50 times the maximum exposure in humans taking an oral dose, based on body surface area. Oxybutynin chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems. Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no definite evidence of impaired fertility.
Package label principal display panel
The content of the principal display panel of the product package, usually including the product’s name, dosage forms, and other key information about the drug product.PRINCIPAL DISPLAY PANEL Gelnique ® (oxybutynin chloride) Gel, 10% Carton 1 Pump NDC 0023-5812-30 PRINCIPAL DISPLAY PANEL Gelnique® (oxybutynin chloride) Gel, 10% Carton 1 Pump NDC 0023-5812-30
PRINCIPAL DIS PLAY PANEL NDC 0023-5861-11 Rx only Gelnique ® (oxybutynin chloride) Gel 10% FOR TOPICAL USE ONLY 30 Sachets Allergan ™ PRINCIPAL DISPLAY PANEL NDC 0023-5861-11 Rx only Gelnique® (oxybutynin chloride) Gel 10% FOR TOPICAL USE ONLY 30 Sachets Allergan™
GELNIQUE: Information for patients
Information necessary for patients to use the drug safely and effectively, such as precautions concerning driving or the concomitant use of other substances that may have harmful additive effects.17 PATIENT COUNSELING INFORMATION See FDA-approved Patient Labeling (Patient Information) Instructions for Use GELNIQUE is for topical application only and should not be ingested. GELNIQUE should not be applied to recently shaved skin surfaces. Patients should wash hands immediately after product application. Application sites should not be subject to showering or water immersion for 1 hour after product application. Application sites should be covered with clothing if close skin-to-skin contact at the application site is anticipated. Alcohol based gels are flammable. Avoid open fire or smoking until the gel has dried. Important Anticholinergic Adverse Reactions Patients should be informed that anticholinergic (antimuscarinic) agents, such as GELNIQUE, may produce clinically significant adverse reactions related to anticholinergic pharmacological activity including: Urinary retention and constipation. Heat prostration (due to decreased sweating) when anticholinergics such as GELNIQUE are used in a hot environment. Dizziness or blurred vision. Patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until GELNIQUE’s effects have been determined. Drowsiness that may be worsened by alcohol. Distributed By: Allergan USA, Inc. Madison, NJ 07940 © 2019 Allergan. All rights reserved. Gelnique ® is a registered trademark of Allergan Sales, LLC. v1.1USPI5812
Spl patient package insert
Information necessary for patients to use the drug safely and effectively.FDA-Approved Patient Labeling PATIENT INFORMATION GELNIQUE [ JEL NEEK ] (oxybutynin chloride) 10% gel Topical IMPORTANT: For use on the skin only (topical). Do not use GELNIQUE in or near your eyes, nose, or mouth. What is GELNIQUE? GELNIQUE is a prescription medicine used to treat the symptoms of overactive bladder: Urge urinary incontinence (a strong need to urinate with leaking or wetting accidents). Urgency (a strong need to urinate right away). Frequency (need to urinate often). Do not use GELNIQUE if : your bladder does not empty or does not empty completely when you urinate (urinary retention). your stomach empties slowly or incompletely after a meal (gastric retention). you have uncontrolled narrow-angle glaucoma (high pressure in your eye). Tell your doctor if you have glaucoma or a family history of glaucoma. you are allergic to oxybutynin or any of the ingredients in GELNIQUE. See the end of this Patient Information leaflet for a complete list of ingredients in GELNIQUE. Before using GELNIQUE, tell your healthcare provider about all of your medical conditions, including , if you: have problems emptying your bladder completely have a gastrointestinal obstruction (blockage in the digestive system) have constipation or difficulty emptying your bowels have ulcerative colitis (inflamed bowels) have gastroesophageal reflux disease (GERD) or esophagitis (inflamed esophagus, the tube between your mouth and stomach) have myasthenia gravis (condition that causes muscle weakness) are pregnant or plan to become pregnant are breastfeeding or plan to breastfeed Especially tell your doctor if you take: medicines called “bisphosphonates” to treat osteoporosis medicines called “anticholinergics” Ask your doctor or pharmacist for a list of these medicines if you are not sure if you take any of these medicines. Know the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I use GELNIQUE? GELNIQUE is for skin use only. Use GELNIQUE exactly as your healthcare provider tells you to use it. GELNIQUE should only be applied to dry intact skin on your stomach (abdomen), upper arms, shoulders, or thighs. Do not put GELNIQUE on open sores, recently shaved skin, or skin with rashes. You should change your application site every day. Do not use the same site 2 days in a row. Changing application sites every day can help reduce your chance of getting skin irritation. GELNIQUE contains alcohol and is flammable. Avoid fire, flames or smoking until GELNIQUE has dried. After applying GELNIQUE, wash your hands with soap and water right away. Cover the application site with clothing if skin-to-skin contact between another person and the application site is expected. If someone else is exposed to GELNIQUE by direct contact with the gel or at the application site, that person should wash the area of contact with soap and water as soon as possible. If you get GELNIQUE in your eyes, rinse your eyes right away with warm, clean water to flush out any GELNIQUE. GELNIQUE may be used with sunscreen. Applying GELNIQUE: 1. Selecting your application site: Apply GELNIQUE only to 1 of the shaded areas shown in the figure below: (See Figure A) stomach (abdomen) upper arms shoulder thigh Figure A : Wash the area where GELNIQUE will be applied with mild soap and water. Allow the area to dry completely. Wash your hands with soap and water. 2. How to use the GELNIQUE packets (sachets): Find the notch at the top of your GELNIQUE packet. Tear off the top of the GELNIQUE packet at the notch (See Figure B). Figure B : Squeeze all of the GELNIQUE out of the packet onto your hand (palm or fingertips) or you can squeeze all of the GELNIQUE from the packet right onto the application site (See Figure C). Squeeze from the bottom of the packet toward the open end. Repeat until the packet is empty. The amount of GELNIQUE in each packet will be about the size of a nickel. Apply GELNIQUE to your skin (shown in Figure C). Figure C : Wash your hands with soap and water right away. Throw away the packet in the trash out of the reach of children to avoid accidental exposure. 3. How to use the GELNIQUE pump: You must prime the GELNIQUE pump before you use it for the first time. To prime the pump: To prime GELNIQUE, hold the pump upright (see Figure D) and fully press down (depress) the pump several times with your thumb or index finger until you see gel come out (typically, this will take four or more depressions). After gel is observed, fully depress the pump one more time, and discard this portion of the product to assure precise dose delivery. The pump is now primed and GELNIQUE is ready to use. Figure D : Dispensing your dose of GELNIQUE: Place your hand under the GELNIQUE pump (see Figure E). Press the pump all the way down 1 time. You can also place the pump right over the application site then press the pump all the way down 1 time to dispense your dose. The amount of gel dispensed with one full pump equals one daily dose of GELNIQUE. The amount of gel that equals your dose will be about the size of a nickel. Figure E: Apply the gel to your skin in the selected body area (see Figure A) and wash your hands with soap and water right away. After you have used GELNIQUE pump 30 times, throw it away. What should I avoid while using GELNIQUE? GELNIQUE can cause tiredness, drowsiness, dizziness or blurred vision. Do not drive, operate machinery, or do other dangerous activities until you know how GELNIQUE affects you. Do not take a bath, swim, shower, exercise, or get the application site wet for at least 1 hour after you apply your dose. What are the possible side effects of GELNIQUE? GELNIQUE can cause serious side effects including: Allergic reactions, including allergic skin reactions The most common side effects of GELNIQUE include: dry mouth redness, rash, itching, pain at the application site dizziness headache constipation itching tiredness Other side effects that have been seen with drugs containing oxybutynin, like GELNIQUE, include: dizziness and blurred vision, drowsiness that may be increased with alcohol (beer, wine, or hard liquor), and decreased sweating that may lead to overheating. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of GELNIQUE. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. How should I store GELNIQUE? Store GELNIQUE at 68°F to 77°F (20°C to 25°C). Safely throw away GELNIQUE in household trash. Be careful to prevent accidental exposure to children or pets. Keep GELNIQUE metered-dose pump and sachets in a dry place. Keep GELNIQUE and all medicines out of the reach of children. General information about GELNIQUE Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use GELNIQUE for a condition for which it was not prescribed. Do not give GELNIQUE to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about GELNIQUE that is written for health professionals. For more information about GELNIQUE call 1-800-678-1605 or go to www.GELNIQUE.com What are the ingredients of GELNIQUE? Active Ingredient: oxybutynin chloride Inactive Ingredients: alcohol, USP; glycerin, USP; hydroxypropyl cellulose, NF; sodium hydroxide, NF; and purified water, USP. This Patient Information has been approved by the U.S. Food and Drug Administration. Distributed By: Allergan USA, Inc. Madison, NJ 07940 © 2019 Allergan. All rights reserved. Gelnique ® is a registered trademark of Allergan Sales, LLC. Revised: 03/2019 v1.1PPI5812 Figure A Figure B Figure C Figure D Figure E
Clinical studies
This field may contain references to clinical studies in place of detailed discussion in other sections of the labeling.14 CLINICAL STUDIES The efficacy and safety of GELNIQUE were evaluated in a single randomized, double-blind, placebo-controlled, parallel group 12-week study for the treatment of overactive bladder with symptoms of urge incontinence, urgency and frequency. Key entry criteria included adults with symptomatic overactive bladder with an average of ≥ 4 incontinence episodes in a 3-day period and at least 8 micturitions per day. Patients were randomized to daily applications of GELNIQUE 1 gram or matching placebo gel. A total of 389 patients received GELNIQUE and 400 patients received placebo gel. The majority of patients were Caucasian (86.3%) and female (89.2%), with a mean age of 59.4 years (range: 18 to 88 years). The average duration of urinary incontinence was approximately 8.5 years and approximately 75% of patients had no prior pharmacological treatment for urinary incontinence. Patients treated with GELNIQUE experienced a statistically significant decrease in the number of urinary incontinence episodes per day from baseline to endpoint compared with placebo (p < 0.0001) as well as a decrease in the average daily urinary frequency (p = 0.0017) and an increase in the average urine volume per void (p = 0.0018). Mean and median change from baseline in daily incontinence episodes (primary endpoint), urinary frequency, and urinary void volume (secondary endpoints) between placebo and GELNIQUE are summarized in Table 3. Table 3: Mean and median change from baseline for incontinence episodes, urinary frequency, and urinary void volume at Week 12 (LOCF*). Parameter GELNIQUE 1 gram (N = 389) Placebo (N = 400) Mean (SD) Median Mean (SD) Median Daily Incontinence Episodes Baseline 5.4 (3.26) 4.7 5.4 (3.28) 4.7 Change from baseline -3.0 (2.73) -2.7 -2.5 (3.06) -2.0 Mean difference [GELNIQUE – placebo] (95% CI) -0.5 (-0.14, -0.87) P-value vs. placebo < 0.0001 Daily Urinary Frequency Baseline 12.4 (3.34) 11.7 12.2 (3.32) 11.3 Change from baseline -2.7 (3.21) -2.7 -2.0 (2.82) -1.7 P-value vs. placebo 0.0017 Urinary Void Volume (mL) Baseline 163.4 (65.85) 160.1 167.9 (68.40) 160.6 Change from Baseline 21.0 (65.33) 11.5 3.8 (53.79) 0.0 P-value vs. placebo 0.0018 *Last-Observation-Carried-Forward statistical imputation for missing data
| | | | ||
| | | | | |
| Daily Incontinence Episodes | ||||
| Baseline | 5.4 (3.26) | 4.7 | 5.4 (3.28) | 4.7 |
| Change from baseline | -3.0 (2.73) | -2.7 | -2.5 (3.06) | -2.0 |
| Mean difference [GELNIQUE – placebo] (95% CI) | -0.5 (-0.14, -0.87) | |||
| P-value vs. placebo | < 0.0001 | |||
| Daily Urinary Frequency | ||||
| Baseline | 12.4 (3.34) | 11.7 | 12.2 (3.32) | 11.3 |
| Change from baseline | -2.7 (3.21) | -2.7 | -2.0 (2.82) | -1.7 |
| P-value vs. placebo | 0.0017 | |||
| Urinary Void Volume (mL) | ||||
| Baseline | 163.4 (65.85) | 160.1 | 167.9 (68.40) | 160.6 |
| Change from Baseline | 21.0 (65.33) | 11.5 | 3.8 (53.79) | 0.0 |
| P-value vs. placebo | 0.0018 | |||
| *Last-Observation-Carried-Forward statistical imputation for missing data | ||||
Geriatric use
Information about any limitations on any geriatric indications, needs for specific monitoring, hazards associated with use of the drug in the geriatric population.8.5 Geriatric Use Of the 496 patients exposed to GELNIQUE in the randomized, double-blind, placebo-controlled 12-week study and the 14-week safety extension study, 188 patients (38%) were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3) ] .
Pediatric use
Information about any limitations on any pediatric indications, needs for specific monitoring, hazards associated with use of the drug in any subsets of the pediatric population (such as neonates, infants, children, or adolescents), differences between pediatric and adult responses to the drug, and other information related to the safe and effective pediatric use of the drug.8.4 Pediatric Use The safety and effectiveness of GELNIQUE 10% have not been established in pediatric patients.
Pregnancy
Information about effects the drug may have on pregnant women or on a fetus. This field may be ommitted if the drug is not absorbed systemically and the drug is not known to have a potential for indirect harm to the fetus. It may contain information about the established pregnancy category classification for the drug. (That information is nominally listed in the teratogenic_effects field, but may be listed here instead.)8.1 Pregnancy Risk Summary There are no studies with topical or oral oxybutynin use in pregnant women to inform any drug-associated risks of adverse development outcomes. No adverse developmental outcomes were observed in animal reproduction studies when oxybutynin chloride was administered to pregnant rats and rabbits during organogenesis at approximately 50 and 1 times, respectively, the maximum human dose based on body surface area ( see Data ). In the general U.S. population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20% respectively. Data A n i m al Da t a Subcutaneous administration of oxybutynin chloride to rats at doses up to 25 mg/kg (approximately 50 times the human exposure based on body surface area) and to rabbits at doses up to 0.4 mg/kg (approximately 1 times the human exposure based on body surface area) throughout the period of organogenesis revealed no evidence of harm to the fetus.
Use in specific populations
Information about use of the drug by patients in specific populations, including pregnant women and nursing mothers, pediatric patients, and geriatric patients.8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no studies with topical or oral oxybutynin use in pregnant women to inform any drug-associated risks of adverse development outcomes. No adverse developmental outcomes were observed in animal reproduction studies when oxybutynin chloride was administered to pregnant rats and rabbits during organogenesis at approximately 50 and 1 times, respectively, the maximum human dose based on body surface area ( see Data ). In the general U.S. population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20% respectively. Data A n i m al Da t a Subcutaneous administration of oxybutynin chloride to rats at doses up to 25 mg/kg (approximately 50 times the human exposure based on body surface area) and to rabbits at doses up to 0.4 mg/kg (approximately 1 times the human exposure based on body surface area) throughout the period of organogenesis revealed no evidence of harm to the fetus. 8.2 Lactation Risk Summary There is no information on the presence of oxybutynin or its metabolites in human milk, its effects on milk production or on the breast fed child. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for GELNIQUE and any potential adverse effects on the breastfed child from GELNIQUE or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of GELNIQUE 10% have not been established in pediatric patients. 8.5 Geriatric Use Of the 496 patients exposed to GELNIQUE in the randomized, double-blind, placebo-controlled 12-week study and the 14-week safety extension study, 188 patients (38%) were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3) ] .
How supplied
Information about the available dosage forms to which the labeling applies, and for which the manufacturer or distributor is responsible. This field ordinarily includes the strength of the dosage form (in metric units), the units in which the dosage form is available for prescribing, appropriate information to facilitate identification of the dosage forms (such as shape, color, coating, scoring, and National Drug Code), and special handling and storage condition information.16 HOW SUPPLIED/STORAGE AND HANDLING Metered-Dose Pump: Metered-dose pump dispenser capable of delivering 30 metered 1 gram doses. Carton of 1 metered-dose Pump (NDC 0023-5812-30) Unit Dose : Heat-sealed sachet containing 1 gram (1.14 mL) of GELNIQUE gel for topical use. Carton of 30 Sachets (NDC 0023-5861-11) Storage Store at 20-25°C (68-77°F). [See USP controlled room temperature.] Protect from moisture and humidity. Apply immediately after the sachets are opened and contents expelled or dose delivered from dispenser. Discard used sachets and empty dispensers in household trash in a manner that prevents accidental application or ingestion by children, pets, or others. Keep out of reach of children.
Disclaimer: Do not rely on openFDA or Phanrmacy Near Me to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Source: OpenFDA, Healthporta Drugs API